Institutional Investors Accumulate Tilray Shares Amid Price Weakness

While Tilray Brands, Inc. shares have continued to face downward pressure following a recent reverse stock split, a significant shift is occurring behind the scenes. Fresh regulatory filings reveal that major institutional players have been building substantial positions, suggesting a divergence between near-term price action and long-term investor conviction.

Major Funds Expand Holdings

Data released on December 8th shows aggressive buying by two prominent investment firms during the third quarter. Millennium Management dramatically increased its stake by 281 percent, bringing its total holding to nearly 5 million shares. In a parallel move, Tidal Investments added over 3.7 million shares to its portfolio, marking a 15.0 percent increase in its position.

This accumulation points to a strategic bet by sophisticated market participants. The activity stands in contrast to the cautious sentiment among some retail investors, highlighting a potential disconnect between short-term trading reactions and the outlook of professional, long-term capital.

Market Context and the Reverse Split

Trading activity remains subdued in the immediate aftermath of the corporate action. On Monday, Tilray’s stock closed at $7.20, down 2.04 percent, with volume approximately 20 percent below its average. This price movement follows the 1-for-10 reverse stock split executed on December 1st.

Should investors sell immediately? Or is it worth buying Tilray?

The primary goal of the split was to optimize the company’s share structure and enhance the stock’s appeal to institutional investors. The recent filings from Millennium and Tidal indicate this strategic objective may already be gaining traction.

Operational Strategy and Key Milestones

Beyond financial engineering, the company is pushing forward with its diversification strategy. Its recently published holiday product catalog emphasizes craft beverages and hemp-based goods, segments designed to counterbalance regulatory delays within the core cannabis market.

From a technical analysis perspective, short-term focus centers on the $7.14 support level established during recent trading. Fundamentally, a critical date looms in January 2026, when Tilray is scheduled to report earnings for the second quarter of its 2026 fiscal year. This report will serve as a crucial early indicator of whether the company’s operational repositioning is translating to tangible financial results.